Plain-English translation of NCT07121777 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a new treatment called LCAR1901, which is a type of gene therapy given as an injection into your bloodstream. The therapy is designed to help people whose autoimmune diseases—such as rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis—have not improved with standard medications. Researchers want to learn whether this medication is safe and whether it can help control these difficult-to-treat conditions.
Many people with autoimmune diseases continue to suffer even after trying multiple standard treatments. This trial exists to explore whether this new gene therapy approach might offer hope to patients whose immune systems remain overactive despite conventional medicines.
You likely qualify if…
You likely don't qualify if…
You will receive a single intravenous injection (through a vein) of the new gene therapy medication at the study site. The study will carefully monitor your safety and how well the treatment works over time through follow-up visits and lab tests. This is a small study enrolling up to 18 participants total, and researchers will start with lower doses and gradually increase them to find the safest and most effective dose.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China
Sponsor
Anhui Provincial Hospital
Enrollment target
~18 participants
Started
August 2025
Primary completion
August 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
chen zhu, M.D
Anhui Provincial Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.